- with
everolimus.[medical
citation needed] A
phase IIa randomized, placebo-controlled
everolimus clinical trial published in 2014
showed that
everolimus improved...
-
responses were noted.
Everolimus is the
second novel Rapamycin analog.
Compared with the
parent compound rapamycin,
everolimus is more
selective for the...
- antibodies. It is also
active against tumors that are PI3K/AKT/mTOR-dependent.
Everolimus is an
analog of
sirolimus and also is an mTOR inhibitor.
Zotarolimus is...
-
Everolimus also
showed evidence of
effectiveness at
treating epilepsy in some
people with TSC. In 2017, the
European Commission approved everolimus for...
-
PanNETs by the FDA
based on
improved progression-free
survival (PFS):
everolimus (Afinitor) is
labeled for
treatment of
progressive neuroendocrine tumors...
-
carcinoma over
everolimus in 2015 and was
approved by the FDA.
Cabozantinib also
demonstrated an
overall survival benefit over
everolimus and was approved...
- (Nimotuzumab),
BLISTO (Glimepiride + Metformin),
CANMAb (Trastuzumab),
Evertor (
Everolimus),
TACROGRAF (Tacrolimus),
ALZUMAb (Itolizumab) and
KRABEVA (Bevacizumab)...
- prednisone, mycophenolate, cyclophosphamide, ciclosporin, tacrolimus,
everolimus,
thymoglobulin and sirolimus. Newer, so-called "biologic drugs" or monoclonal...
- BEZ235/Dactolisib was
administered in
combination with the mTOR
inhibitor Everolimus. The
authors concluded that the
combination of both
drugs demonstrated...
- immuno****ay and
latex agglutination turbidimetric immuno****ay for
evaluation of
everolimus blood concentrations in
renal transplant patients".
Journal of Clinical...
